benzyl (1S,4S,5S)-4-(1-methyl-1H-tetrazol-5-ylsulfanyl)-7-oxo-2,6-diazabicyclo<3.2.0>heptanecarboxylate | 214837-35-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl (1S,4S,5S)-4-(1-methyl-1H-tetrazol-5-ylsulfanyl)-7-oxo-2,6-diazabicyclo<3.2.0>heptanecarboxylate
• CAS: 214837-35-1
• 化学式: C₁₅H₁₆N₆O₃S
• 分子量: 360.396
• InChiKey: JSRKVLZAJAULLY-TUAOUCFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.19
• 重原子数：
  25.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  102.24
• 氢给体数：
  1.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  benzyl (1S,4S,5S)-4-(1-methyl-1H-tetrazol-5-ylsulfanyl)-7-oxo-2,6-diazabicyclo<3.2.0>heptanecarboxylate 在 三氧化硫 N,N-二甲基甲酰胺络合物 作用下， 反应 4.0h， 以10%的产率得到Sodium; (1S,4R,5S)-2-benzyloxycarbonyl-4-(1-methyl-1H-tetrazol-5-ylsulfanyl)-7-oxo-2,6-diaza-bicyclo[3.2.0]heptane-6-sulfonate
  参考文献：
  名称：

  Structure-Based Design of β-Lactamase Inhibitors. 1. Synthesis and Evaluation of Bridged Monobactams

  摘要：

  Bridged monobactams are novel, potent, mechanism-based inhibitors of class C beta-lactamases, designed using X-ray crystal structures of the enzymes. They stabilize the acyl-enzyme intermediate by blocking access of water to the enzyme-inhibitor ester bond. Bridged monobactams are selective class C beta-lactamase inhibitors, with half-inhibition constants as low as 10 nM, and are less effective against class A and class B enzymes (half-inhibition constants > 100 mu M) because of the different hydrolysis mechanisms in these classes of beta-lactamases. The stability of the acyl-enzyme complexes formed with class C beta-lactamases (half-lives up to 2 days were observed) enabled determination of their crystal structures. The conformation of the inhibitor moiety was close to that predicted by molecular modeling, confirming a simple reaction mechanism, unlike those of known beta-lactamase inhibitors such as clavulanic acid and penam sulfones, which involve secondary rearrangements. Synergy between the bridged monobactams and beta-lactamase-labile antibiotics could be observed when such combinations were tested against strains of Enterobacteriaceae that produce large amounts of class C beta-lactamases. The minimal inhibitory concentration of the antibiotic of more than 64 mg/L could be decreased to 0.25 mg/L in a 1:4 combination with the inhibitor.

  DOI：

  10.1021/jm980023c
• 作为产物：
  描述：

  (1S,4S,5S)-2-(benzyloxycarbonyl)-4-(tetrahydropyran-2-yloxy)-2,6-diazabicyclo<3.2.0>heptan-7-one 在 吡啶 、 4-甲基苯磺酸吡啶 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 98.0h， 生成 benzyl (1S,4S,5S)-4-(1-methyl-1H-tetrazol-5-ylsulfanyl)-7-oxo-2,6-diazabicyclo<3.2.0>heptanecarboxylate
  参考文献：
  名称：

  Structure-Based Design of β-Lactamase Inhibitors. 1. Synthesis and Evaluation of Bridged Monobactams

  摘要：

  Bridged monobactams are novel, potent, mechanism-based inhibitors of class C beta-lactamases, designed using X-ray crystal structures of the enzymes. They stabilize the acyl-enzyme intermediate by blocking access of water to the enzyme-inhibitor ester bond. Bridged monobactams are selective class C beta-lactamase inhibitors, with half-inhibition constants as low as 10 nM, and are less effective against class A and class B enzymes (half-inhibition constants > 100 mu M) because of the different hydrolysis mechanisms in these classes of beta-lactamases. The stability of the acyl-enzyme complexes formed with class C beta-lactamases (half-lives up to 2 days were observed) enabled determination of their crystal structures. The conformation of the inhibitor moiety was close to that predicted by molecular modeling, confirming a simple reaction mechanism, unlike those of known beta-lactamase inhibitors such as clavulanic acid and penam sulfones, which involve secondary rearrangements. Synergy between the bridged monobactams and beta-lactamase-labile antibiotics could be observed when such combinations were tested against strains of Enterobacteriaceae that produce large amounts of class C beta-lactamases. The minimal inhibitory concentration of the antibiotic of more than 64 mg/L could be decreased to 0.25 mg/L in a 1:4 combination with the inhibitor.

  DOI：

  10.1021/jm980023c